# A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

> **NCT06240351** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 15 (estimated)

## Conditions studied

- Frontal Fibrosing Alopecia

## Interventions

- **DRUG:** Baricitinib 4 MG Oral Tablet

## Key facts

- **NCT ID:** NCT06240351
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06240351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06240351, "A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06240351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*